MVN Asset Management Limited Form 8.3 - Quantum Pharma PLC (9949U)
31 October 2017 - 12:56AM
UK Regulatory
TIDMQP.
RNS Number : 9949U
MVN Asset Management Limited
30 October 2017
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1%
OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: MVN Asset Management Limited
--------------------------------------------------------------------------------------- -----------------------------
(b) Owner or controller of interests and short positions disclosed, if different from N/A
1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the
trustee(s),
settlor and beneficiaries must be named.
--------------------------------------------------------------------------------------- -----------------------------
(c) Name of offeror/offeree in relation to whose relevant securities this form Quantum Pharma plc
relates:
Use a separate form for each offeror/offeree
--------------------------------------------------------------------------------------- -----------------------------
(d) If an exempt fund manager connected with an offeror/offeree, state this and N/A
specify identity
of offeror/offeree:
--------------------------------------------------------------------------------------- -----------------------------
(e) Date position held/dealing undertaken: 27/10/2017
For an opening position disclosure, state the latest practicable date prior to the
disclosure
--------------------------------------------------------------------------------------- -----------------------------
(f) In addition to the company in 1(c) above, is the discloser making disclosures in CLINIGEN GROUP PLC
respect
of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
--------------------------------------------------------------------------------------- -----------------------------
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following
the dealing (if any)
Class of relevant security: 10p ordinary
---------------------------------------------------------------------------- ----------------------------------------
Interests Short positions
-------------------- ------------------
Number % Number %
---------------------------------------------------------------------------- ----------- ------- ------------- ---
(1) Relevant securities owned and/or controlled: 19,533,261 11.55% 0 0
---------------------------------------------------------------------------- ----------- ------- ------------- ---
(2) Cash-settled derivatives: 0 0 0 0
---------------------------------------------------------------------------- ----------- ------- ------------- ---
(3) Stock-settled derivatives (including options) and agreements to
purchase/sell: 0 0 0 0
---------------------------------------------------------------------------- ----------- ------- ------------- ---
TOTAL: 19,533,261 11.55% 0 0
---------------------------------------------------------------------------- ----------- ------- ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
----------------------------------------------------------------------------
Details, including nature of the rights concerned and relevant percentages:
----------------------------------------------------------------------------
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
Class of relevant security Purchase/sale Number of securities Price per unit
---------------------------- --------------- --------------------- ---------------
10p ordinary Purchase 36,248 82.833537p
---------------------------- --------------- --------------------- ---------------
10p ordinary Purchase 52,473 82.833537p
---------------------------- --------------- --------------------- ---------------
(b) Cash-settled derivative transactions
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing a securities
long/short position,
increasing/reducing a
long/short position
------------------------- -------------------- ------------------------- ------------------------- ---------------
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry date Option money
relevant description purchasing, securities price per e.g. paid/
security e.g. call selling, to which unit American, received per
option varying etc. option European unit
relates etc.
------------- ------------- ------------- ------------- -------------- ------------- ------------ -------------
(ii) Exercise
Class of relevant Product description Exercising/ exercised Number of securities Exercise price per
security e.g. call option against unit
----------------------- -------------------- ----------------------- --------------------- -----------------------
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
--------------------------- ------------------------------- -------- -------------------------------
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the person making the disclosure and any party to the offer or
any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
---------------------------------------------------------------------------------------------
None
---------------------------------------------------------------------------------------------
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person
making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
-----------------------------------------------------------------------------------------------
None
-----------------------------------------------------------------------------------------------
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? No
---------------------------------------------------- ---
Date of disclosure: 30/10/2017
--------------------- -----------------
Contact name: Peter Teng
--------------------- -----------------
Telephone number: +44 20 3876 8718
--------------------- -----------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service.
The Panel's Market Surveillance Unit is available for
consultation in relation to the Code's disclosure requirements on
+44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RETEADEEDSLXFFF
(END) Dow Jones Newswires
October 30, 2017 09:56 ET (13:56 GMT)
Quantum Phar. (LSE:QP.)
Historical Stock Chart
From Oct 2024 to Nov 2024
Quantum Phar. (LSE:QP.)
Historical Stock Chart
From Nov 2023 to Nov 2024